Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + CG1940/CG8711 vs Docetaxel + Prednisone in Metastatic Hormone-Refractory Prostate Cancer
2005-003275-20Phase 3Terminated
- Sponsor
- BioSante Pharmaceuticals
- Start
- Jul 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Docetaxel + CG1940 + CG8711 with Docetaxel + Prednisone (2 arms). Primary endpoint: Overall survival. Started Jul 2005; status: terminated.
02
Drugs
autologous RCC vaccinedocetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2005-003275-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003275-20.